Integrum AB (publ) (INTEG_B) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to today's presentation, where we have Integrum presenting their Q2 report. With us presenting, we have Acting CEO, Scott Flora, and CFO, Juergen Svonström. If you have any questions, please use the form located to the right, and we'll take that up during the Q&A after the presentation. And with that said, please go ahead with your presentation. Juergen? Yeah, here we can see the agenda for today. We will have a brief introduction from Scott and then a business update. And myself, I will do a financial update. And after that, a summary and some Q&A at the end. So with that said, over to you, Scott. Thanks. Thanks, Jorgen, and good morning. if you're here in the East Coast US and good afternoon to all of you in Sweden. And I'm very happy to present this Q2 report today and spend a little more time on what we think are the critical things the company needs to do. First, why do I get involved with Integra and why am I here? This is a phenomenal product. If you look at the orthopedic marketplace, hasn't been a lot of true innovation and a lot of PMAs that have been done that really impact patients lives the way we do. And, and therefore I think this is a real game changing device. Now with that, we're on a, we're on a market adoption journey. And with that market adoption journey, there's some key levers that we need to execute better on. The team here at Intagram, we're really not very happy with the, our second quarter results with the exception of the bright spot in the S1 surgeries returning in the US. But we know we've got to execute better against driving market adoption. And what that means for the team, it's not an easy thing. We're changing how we think around just being a science company to transitioning to more of a commercial execution comp...